MENU ▼
Read by QxMD icon Read
search
OPEN IN READ APP
JOURNAL ARTICLE

Prophylactic Fentanyl Sublingual Spray for Episodic Exertional Dyspnea in Cancer Patients: A Pilot Double-Blind Randomized Controlled Trial

David Hui, Farley Hernandez, Liliana Larsson, Diane Liu, Kelly Kilgore, Jane Naberhuis, Avery Virgilio, Suresh Reddy, Akhila Reddy, Shalini Dalal, Ali Haider, Larry Driver, Ahsan Azhar, Rony Dev, Eduardo Bruera
Journal of Pain and Symptom Management 2019 July 2
31276809

CONTEXT: The optimal dose of fentanyl sublingual spray (FSS) for exertional dyspnea has not been determined.

OBJECTIVE: We examined the effect of two doses of prophylactic FSS on exertional dyspnea.

METHODS: In this parallel, dose-finding, double-blind randomized clinical trial, opioid-tolerant cancer patients completed a shuttle walk test at baseline. Patients completed a second shuttle walk test 10 minutes after a single dose of FSS equivalent to either 35-45% (high dose) or 15-25% (low dose) of the total daily opioid dose. The primary outcome was change in modified dyspnea Borg scale (0-10) between the first and second shuttle walk tests. Secondary outcomes included adverse events as well as changes in walk distance, vital signs, and neurocognitive function.

RESULTS: Thirty of the 50 enrolled patients completed the study. High dose FSS (n=13) resulted in significantly lower dyspnea (mean change -1.42; 95% CI -2.37, -0.48; P=0.007) and greater walk distance (mean change 44 m; P=0.001) compared to baseline. Low dose FSS (n=17) resulted in a non-significant reduction in dyspnea (mean change -0.47; 95% CI -1.26, 0.32; P=0.24) and significant increase in walk distance (mean change 24 m; P=0.01) compared to baseline. Global evaluation showed high dose group was more likely to report at least somewhat better improvement (64% vs. 24%; P=0.06). No significant adverse events or detriment to vital signs or neurocognitive function were detected.

CONCLUSIONS: Prophylactic FSS was well tolerated and demonstrated a dose-response relationship in improving both dyspnea and walk distance. High dose FSS should be tested in confirmatory trials.

Comments

You need to log in or sign up for an account to be able to comment.

No comments yet, be the first to post one!

Related Papers

Available on the App Store

Available on the Play Store
Remove bar
Read by QxMD icon Read
31276809
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"